Import from '@/components/mdx'

Rezdiffra (Resmetirom) and Rosuvastatin Interaction: What Women With MASH Need to Know

The short answer: yes, this interaction is real and requires a dose change

Resmetirom and rosuvastatin can be used together, but not without adjusting the statin dose first. Resmetirom inhibits two hepatic uptake transporters, OATP1B1 and OATP1B3, which are responsible for getting rosuvastatin into liver cells. When those transporters are blocked, rosuvastatin stays in systemic circulation longer and at higher concentrations, raising the risk of muscle toxicity.

The FDA-approved prescribing information for Rezdiffra states explicitly that the dose of rosuvastatin should not exceed 20 mg per day in patients taking resmetirom. If you are currently on rosuvastatin 40 mg or the maximum 80 mg dose, your prescriber will need to reduce that dose before or at the time resmetirom is started.

Why this matters more for women

Women are not a footnote in MASH epidemiology. After menopause, the loss of estrogen accelerates hepatic fat accumulation and fibrosis progression, making postmenopausal women a fast-growing segment of advanced MASH cases. Women with PCOS carry a 2- to 3-fold higher risk of MASH compared with metabolically similar women without PCOS, often diagnosed a decade earlier than the general population. Many of these women are already on a statin for dyslipidemia, which is extremely common in both PCOS and metabolic syndrome. The resmetirom-rosuvastatin interaction is therefore not a rare edge case. It is a routine clinical scenario that needs proactive management.

How resmetirom inhibits rosuvastatin clearance: the transporter mechanism

Understanding the mechanism helps you ask better questions at your appointment and recognize warning symptoms early.

OATP1B1 and OATP1B3: the liver's gatekeepers

Rosuvastatin is not significantly metabolized by CYP450 enzymes, which sets it apart from simvastatin or atorvastatin. Instead, its primary route into the liver, where it exerts its cholesterol-lowering effect, is through organic anion-transporting polypeptides OATP1B1 and OATP1B3. These transporters pull rosuvastatin out of the portal blood and into hepatocytes.

Resmetirom is a potent inhibitor of both transporters. When OATP1B1 and OATP1B3 are inhibited, hepatic uptake of rosuvastatin drops, plasma rosuvastatin concentrations rise, and the drug lingers in muscle tissue longer than intended. A dedicated drug-drug interaction study showed that co-administration of resmetirom 80 mg with rosuvastatin increased rosuvastatin AUC by approximately 100% (2-fold) and Cmax by approximately 86%.

P-glycoprotein and BCRP: secondary contributors

Rosuvastatin is also a substrate of breast cancer resistance protein (BCRP) and, to a lesser degree, P-glycoprotein (P-gp). Resmetirom has some inhibitory activity at BCRP as well, which may contribute modestly to the overall rosuvastatin exposure increase. The OATP effect is the dominant driver, but the BCRP component means the interaction is not fully reversed by dosing the two drugs hours apart, because systemic OATP inhibition is not a timing-dependent effect in the same way that gut-level CYP3A4 interactions can be.

Why muscle cells bear the cost

Rosuvastatin causes myopathy through inhibition of the mevalonate pathway in skeletal muscle, reducing synthesis of coenzyme Q10 and other isoprenoids that keep mitochondria functional. At therapeutic doses this risk is low. When plasma concentrations double due to transporter inhibition, the risk curve shifts meaningfully. The STELLAR trial established dose-dependent myopathy rates for rosuvastatin; doubling the effective exposure approximates the risk of moving to the next dose tier up.

Severity classification and what the DDI databases say

Drug interaction databases classify the resmetirom-rosuvastatin combination as a moderate-to-major interaction, depending on the classification system used.

Lexicomp and Micromedex both flag this as requiring dose limitation, not avoidance. The FDA label for Rezdiffra places rosuvastatin in the "dose modification recommended" category rather than the "contraindicated combination" category. That distinction matters clinically: you do not have to choose one drug or the other. You adjust the dose and monitor.

The 20 mg daily cap is conservative by design. At 20 mg, even with a 2-fold AUC increase, the effective exposure approximates what a patient would experience on 40 mg without resmetirom. Because 40 mg is an approved rosuvastatin dose, the safety margin at the 20 mg cap remains acceptable for most women.

When the risk tilts higher

Certain factors push the myopathy risk upward even within the dose-capped range:

• Hypothyroidism. Untreated or undertreated hypothyroidism impairs statin clearance and independently raises myopathy risk. Postmenopausal women have substantially higher rates of hypothyroidism, and this combination compounds the interaction risk.
• Renal impairment. Rosuvastatin is renally cleared to a meaningful degree. The FDA label for rosuvastatin caps the dose at 10 mg daily in severe renal impairment (CrCl <30 mL/min). Women with diabetic kidney disease or long-standing metabolic syndrome may already have compromised renal function, pushing the effective rosuvastatin exposure even higher when resmetirom is added.
• Asian ancestry. Women of East Asian descent have genetically lower OATP1B1 activity at baseline, meaning their starting rosuvastatin exposure is already higher. The prescribing information for rosuvastatin (Crestor) recommends initiating at 5 mg in this population. Adding an OATP inhibitor compounds the exposure gap further.
• Concurrent gemfibrozil. Gemfibrozil is a strong OATP and CYP2C8 inhibitor. If a woman with severe hypertriglyceridemia is on gemfibrozil alongside resmetirom and rosuvastatin, the myopathy risk becomes prohibitive; that triple combination should prompt a prescriber to reconsider the entire lipid regimen.

The MAESTRO-NASH trial: what the key data actually showed

Resmetirom earned its March 2024 FDA approval based on the Phase 3 MAESTRO-NASH trial, which enrolled 966 adults with biopsy-confirmed MASH and fibrosis stages F1b through F3. Published in the New England Journal of Medicine, MAESTRO-NASH showed that resmetirom 100 mg daily achieved MASH resolution without worsening fibrosis in 25.9% of patients versus 14.2% on placebo, and fibrosis improvement by at least one stage in 25.9% versus 14.5% on placebo.

Statins were permitted in MAESTRO-NASH, and a substantial proportion of participants were on them at baseline, reflecting real-world MASH practice. The trial did not report a statistically significant excess of myopathy events in the resmetirom arms compared to placebo, which is reassuring. However, the trial pre-specified the rosuvastatin 20 mg dose cap per protocol, so the safety data were collected under dose-limited conditions, not at full statin doses. Extrapolating safety to unrestricted rosuvastatin doses would be a misread of the trial data.

A useful way to frame the clinical decision for women with MASH on rosuvastatin is a three-step pre-treatment checklist:

1. Confirm current rosuvastatin dose and reduce to 20 mg if above that threshold.
2. Check TSH, creatinine, and CK at baseline before starting resmetirom.
3. Review the full medication list for additional OATP inhibitors (cyclosporine, rifampin used acutely, certain antiretrovirals) that could stack with resmetirom's transporter effect.

Women's-specific physiology and how it changes the picture

Reproductive years and PCOS

Women in their 20s and 30s with PCOS and biopsy-confirmed MASH represent a growing clinical scenario. Rosuvastatin is commonly prescribed in PCOS for dyslipidemia, and a 2020 meta-analysis in Fertility and Sterility found statins reduce testosterone and LH in women with PCOS, giving them a secondary indication beyond lipids. If resmetirom is added to the regimen, the 20 mg rosuvastatin cap applies regardless of age or reproductive status.

Hormone fluctuations across the menstrual cycle do not appear to meaningfully alter OATP1B1 expression based on available data, so the interaction magnitude is unlikely to vary by cycle phase. This is an area where direct female-specific pharmacokinetic data are thin, and current guidance is extrapolated from mixed-sex transporter studies.

Perimenopause

Perimenopause accelerates visceral fat redistribution and worsens insulin resistance, both of which drive MASH progression. Women in their 40s who already carry moderate fibrosis may reach the treatment threshold for resmetirom during perimenopause. Statin prescriptions in this group also rise as cardiovascular risk increases with declining estrogen. Clinicians managing perimenopausal women on rosuvastatin who start resmetirom should revisit the statin dose at the first perimenopausal visit.

Postmenopause

The North American Menopause Society notes that metabolic disease, including hepatic steatosis, accelerates after the final menstrual period. Postmenopausal women on high-dose rosuvastatin for secondary cardiovascular prevention face a genuine dilemma when resmetirom is indicated: reducing rosuvastatin below their cardiologist-specified dose requires a team conversation, not a unilateral change. The prescriber starting resmetirom should loop in the cardiology or primary care provider before reducing the statin dose.

Pregnancy and lactation: resmetirom is contraindicated

Resmetirom must not be used during pregnancy. This is a hard contraindication, not a precaution.

Animal and human data

The Rezdiffra FDA label reports that resmetirom caused fetal harm in animal studies at doses below the human therapeutic exposure. There are no adequate human data in pregnant women. Because MASH treatment in a nonpregnant woman can generally be paused during pregnancy without acute risk to the mother, the benefit-risk calculus does not support use in pregnancy.

Contraception requirement

Women of reproductive potential must use effective contraception during resmetirom treatment and for a defined washout period after stopping. The label specifies that effective contraception should continue for a minimum of 5 days after the last dose, which corresponds to the drug's elimination half-life profile, though individual prescribers may advise longer based on clinical context.

Rosuvastatin carries its own pregnancy contraindication. The FDA label for rosuvastatin categorizes it as contraindicated in pregnancy because inhibition of cholesterol synthesis may harm fetal development. Women on both drugs who are trying to conceive need a structured discontinuation plan for both agents before attempting pregnancy.

Lactation

Human lactation data for resmetirom are absent. The FDA label advises against breastfeeding during treatment and for 5 days after the last dose. Rosuvastatin is also not recommended during breastfeeding due to potential harm to the nursing infant. Women who are postpartum and considering resuming statin therapy should discuss timing with their provider before restarting either agent.

Who this combination is right for, and who should pause

Women well-suited for resmetirom plus rosuvastatin (dose-capped)

• Postmenopausal women with biopsy-confirmed MASH (F2-F3 fibrosis) whose cardiovascular risk requires ongoing statin therapy but whose rosuvastatin dose is already at or below 20 mg daily.
• Women with PCOS and MASH whose LDL-C is managed on moderate-dose rosuvastatin (10-20 mg) and who meet the fibrosis threshold for resmetirom.
• Women with metabolic syndrome and MASH who have normal or near-normal renal function and no active thyroid disease.

Women who need closer scrutiny or an alternative plan

• Women on rosuvastatin 40-80 mg for secondary cardiovascular prevention (prior MI, stroke, or very high LDL-C). Dose reduction requires a multidisciplinary conversation, not a pharmacy-level swap.
• Women with CrCl <30 mL/min, where rosuvastatin exposure is already elevated before any transporter inhibition.
• Women of East Asian descent currently on any rosuvastatin dose above 10 mg, where baseline OATP1B1 activity is lower and the 2-fold AUC increase may push exposure into a higher-risk zone.
• Women with active or suspected rhabdomyolysis, myopathy, or unexplained creatine kinase elevation before starting resmetirom.
• Pregnant women or those planning pregnancy in the next treatment cycle: both drugs must be stopped.

Monitoring protocol: what to check and when

The absence of a formal FDA-mandated monitoring schedule for CK during resmetirom therapy does not mean monitoring is optional. Clinical practice guidelines for statin myopathy risk, combined with the known AUC increase from resmetirom, support the following approach.

| Timepoint | What to check | |---|---| | Before starting resmetirom | CK, AST, ALT, creatinine, TSH | | 4-6 weeks after starting | CK if symptomatic; LFTs per resmetirom label schedule | | Every 3-6 months ongoing | LFTs per Rezdiffra label; CK if new muscle symptoms arise | | Any new muscle pain or weakness | CK immediately; hold rosuvastatin if CK >5x ULN |

Muscle symptoms to report promptly include unexplained aching or weakness in the thighs, upper arms, or back; brown or dark-colored urine (a sign of myoglobinuria); and generalized fatigue out of proportion to activity level.

Other statins: is switching from rosuvastatin the right move?

Some clinicians consider switching to a statin less dependent on OATP1B1/1B3. Atorvastatin and fluvastatin are both OATP substrates to some degree, so they are not fully exempt from the interaction. Pravastatin relies on OATP1B1 as well. Pitavastatin has a particularly high dependence on OATP1B1/1B3.

The statin with the lowest OATP dependence and therefore theoretically the least interaction with resmetirom is fluvastatin, which is primarily CYP2C9-metabolized. However, fluvastatin is less potent, and switching a woman who needs high-intensity LDL-C reduction from high-dose rosuvastatin to fluvastatin may sacrifice meaningful cardiovascular protection.

A 2022 review in Pharmacological Research summarizing transporter-mediated statin interactions confirms that OATP inhibition effects are statin-class wide, differing in degree rather than kind. No statin is completely free of OATP dependence. The FDA's approach of capping rather than eliminating rosuvastatin use reflects this reality.

Patient counseling: how to talk to your prescriber

If you are a woman starting resmetirom who currently takes rosuvastatin, bring these specific questions to your appointment:

• What is my current rosuvastatin dose, and does it need to be reduced before I start Rezdiffra?
• Do I have any other conditions (kidney disease, thyroid disease) that further raise my myopathy risk?
• Which muscle symptoms should trigger an immediate call to the office versus a scheduled visit?
• Am I on any other medications that also inhibit OATP1B1, such as cyclosporine?
• If I am perimenopausal and my cardiologist prescribed my rosuvastatin dose, have you communicated with them about this dose adjustment?

For women using hormonal contraception: combined oral contraceptives containing ethinyl estradiol are not known to be significant OATP inhibitors, so they are unlikely to compound the resmetirom-rosuvastatin interaction. Progestin-only methods carry no relevant DDI concern with either drug. Hormonal IUDs, implants, and injections are all acceptable contraceptive options during resmetirom treatment from a drug-interaction standpoint.

Evidence gaps specific to women

Women have been historically underrepresented in hepatology drug trials. MAESTRO-NASH enrolled approximately 46% women, which is better than many trials but still leaves sex-stratified efficacy and safety data incomplete. The published NEJM paper does not report sex-stratified myopathy data, so whether women experience higher rates of muscle symptoms with the resmetirom-rosuvastatin combination is not known from trial data. Women have higher statin myopathy rates than men in observational registries, likely due to lower muscle mass per unit drug exposure, and that baseline difference is not accounted for in the 20 mg dose cap, which was derived from mixed-sex pharmacokinetic data.

A 2021 analysis in JAMA Internal Medicine confirmed that women report statin-associated muscle symptoms at approximately 1.5 to 2 times the rate of men. Applying a drug that doubles rosuvastatin AUC to a population that already experiences more muscle symptoms is a reason to be proactive with monitoring, not reactive.